Nanocarriers for pulmonary administration of peptides and therapeutic proteins

Nanomedicine

Volumn 6, Issue 1, 2011, Pages 123-141

  Andrade, Fernanda ^a   Videira, Mafalda ^b   Ferreira, Domingos ^a   Sarmento, Bruno ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

Author keywords

inhalation; nanocarriers; noninvasive delivery; peptides; therapeutic proteins

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; BETA INTERFERON; CALCITONIN; CETRORELIX; CONSENSUS INTERFERON; CYCLOSPORIN A; DEOXYRIBONUCLEASE; DESMOPRESSIN; DETIRELIX; DORNASE ALFA; ERYTHROPOIETIN; FOLLITROPIN; GAMMA INTERFERON; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HUMAN GROWTH HORMONE; INSULIN; LEUPRORELIN; NANOCARRIER; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2; SALCATONIN; SOMATOSTATIN 28; UNINDEXED DRUG;

BONE METASTASIS; CARDIOVASCULAR DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG PENETRATION; HUMAN; HYDROPHILICITY; HYPERCALCEMIA; HYPOGLYCEMIA; KIDNEY CARCINOMA; LIPOPHILICITY; LIVER TOXICITY; LUNG METASTASIS; MEMBRANE TRANSPORT; METERED DOSE INHALER; MYELOMA; NAUSEA; NEBULIZER; NEPHROTOXICITY; NONHUMAN; NOSE SECRETION; OSTEOPOROSIS; PAGET BONE DISEASE; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POWDER INHALER; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; SIDE EFFECT;

ADMINISTRATION, INHALATION; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; PEPTIDES; PROTEINS;

EID: 78650641554     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.143     Document Type: Review

References (134)

1. Umashankar M, Sachdeva R, Gulati M: Aquasomes: a promising carrier for peptides and protein delivery. Nanomedicine 6, 419-426 (2010).
2. Klingler C, Müller B, Steckel H: Insulin-micro-and nanoparticles for pulmonary delivery. Int. J. Pharm. 377(1-2), 173-179 (2009).
3. Amidi M, Mastrobattista E, Jiskoot W, Hennink W: Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 62(1), 59-82 (2010).
4. Sarmento B, Ribeiro A, Veiga F, Ferreira D: Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf. B Biointerfaces 53(2), 193-202 (2006).
5. Bayat A, Dorkoosh F, Dehpour A et al.: Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int. J. Pharm. 356(1-2), 259-266 (2008).
6. Bailey M, Berkland C: Nanoparticle formulations in pulmonary drug delivery Med. Res. Rev. 29(1), 196-212 (2009).
7. Nyambura B, Kellaway I, Taylor K: Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers. Int. J. Pharm. 375(1-2), 114-122 (2009).
8. Sung J, Pulliam B, Edwards D: Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25(12), 563-570 (2007).
9. Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W: Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70(1-2), 1-20 (2001).
10. Martins S, Sarmento B, Ferreira D, Souto E: Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. J. Nanomedicine 2(4), 595-607 (2007).
11. Tauzin B: Biotechnology Medicines in Development. Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC, USA (2008).
12. EvaluatePharma®: World preview to 2016. EvaluatePharma Ltd, London, UK(2010).
13. Tang L, Meibohm B: Pharmacokinetics of peptides and proteins. In: Pharmacokinetics and Pharmacodynamics of Biotech Drugs - Principles and Case Studies in Drug Development. Meibohm B (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2006).
14. Hillery A: Drug delivery: The basic concepts. In: Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. Hillery A, Lloyd A, Swarbrick J (Eds). Taylor & Francis, London, UK (2001).
15. Morishita M, Peppas N: Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11(19-20), 905-910 (2006).
16. Antosova Z, Mackova M, Kral V, Macek T: Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 27(11), 628-635 (2009).
17. Cryan S: Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7(1), E20-E41 (2005).
18. Cryan S, Sivadas N, Garcia-Contreras L: In vivo animal models for drug delivery across the lung mucosal barrier. Adv. Drug Deliv. Rev. 59(11), 1133-1151 (2007).
19. Iazzetti G, Rigutti E (Eds): Atlas of Anatomy. Taj Books, Surrey, UK (2005).
20. Yang W, Peters J, Williams RR: Inhaled nanoparticles - a current review. Int. J. Pharm. 356(1-2), 239-247 (2008).
21. Groneberg D, Fischer A, Chung K, Daniel H: Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am. J. Respir. Cell Mol. Biol. 30(3), 251-260 (2004).
22. Grenha A, Carrión-Recio D, Teijeiro-Osorio D, Seijo B, Remuñán-López C (Eds): Nano and Microparticulate Carriers for Pulmonary Drug Delivery. American Scientifc Publishers, Valencia, CA, USA (2008).
23. Tomoda K, Ohkoshi T, Nakajima T, Makino K: Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerfaces 64(1), 70-76 (2008).
24. Smola M, Vandamme T, Sokolowski A: Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine 3(1), 1-19 (2008).
25. Cefalu W: Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 27(1), 239-246 (2004). (Pubitemid 38196739)
26. Kim K, Malik A: Protein transport across the lung epithelial barrier. Am. J. Physiol Lung Cell. Mol. Physiol. 284(2), L247-L259 (2003).
27. Hastings R, Folkesson H, Matthay M: Mechanisms of alveolar protein clearance in the intact lung. Am. J. Physiol. Lung Cell Mol. Physiol. 286(4), L679-L689 (2004).
28. Berthiaume Y, Albertine K, Grady M, Fick G, Matthay M: Protein clearance from the air spaces and lungs of unanesthetized sheep over 144 h. J. Appl. Physiol. 67(5), 1887-1897 (1989).
29. Agu R, Ugwoke M, Armand M, Kinget R, Verbeke N: The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2(4), 198-209 (2001).
30. Pezron I, Mitra R, Pal D, Mitra A: Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (calu-3). J. Pharm. Sci. 91(4), 1135-1146 (2002).
31. Folkesson H, Weström B, Karlsson B: Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol. Scand. 139(2), 347-354 (1990).
32. Conhaim R, Watson K, Lai-Fook S, Harms B: Transport properties of alveolar epithelium measured by molecular hetastarch absorption in isolated rat lungs. J. Appl. Physiol. 91(4), 1730-1740 (2001).
33. Holter J, Weiland J, Pacht E, Gadek J, Davis W: Protein permeability in the adult respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium. J. Clin. Invest. 78(6), 1513-1522 (1986).
34. Matsukawa Y, Yamahara H, Yamashita F, Lee V, Crandall E, Kim K: Rates of protein transport across rat alveolar epithelial cell monolayers. J. Drug Target 7(5), 335-342 (2000).
35. Bahadduri P, D'souza V, Pinsonneault J et al.: Functional characterization of the peptide transporter pept2 in primary cultures of human upper airway epithelium. Am. J. Respir. Cell Mol. Biol. 32(4), 319-325 (2005).
36. Islam N, Gladki E: Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int. J. Pharm. 360(1-2), 1-11 (2008).
37. Brunton L, Lazo J, Parker K (Eds): Goodman & Gilman's The Pharmacological Basis of therapeutics. McGraw-Hill Professional, Berkshire, UK (2006).
38. Katzung B (Ed.): Basic & Clinical Pharmacology. Lange Medical Books/ McGraw-Hill, New York, NY, USA (2001).
39. Cheng K, Mahato R: Biopharmaceutical challenges: pulmonary delivery of proteins and peptides. In: Pharmacokinetics and Pharmacodynamics of Biotech Drugs - Principles and Case Studies in Drug Development, Meibohm B (Ed.): Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2006).
40. Wolzt M, De La Peña A, Berclaz P, Tibaldi F, Gates J, Muchmore D: Air inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Diabetes Care 31(4), 735-740 (2008).
41. De Galan B, Simsek S, Tack C, Heine R: Effcacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth. J. Med. 64(9), 319-325 (2006).
42. Skyler J, Cefalu W, Kourides I et al.: Effcacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357(9253), 331-335 (2001). (Pubitemid 32128537)
43. Rosenstock J, Cefalu W, Hollander P et al.: Two-year pulmonary safety and effcacy of inhaled human insulin (Exubera) in adult patients with Type 2 diabetes. Diabetes Care 31(9), 1723-1728 (2008).
44. Karathanasis E, Bhavane R, Annapragada A: Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats. Int. J. Nanomedicine 2(3), 501-513 (2007).
45. Ungaro F, D'emmanuele Di Villa Bianca R, Giovino C et al.: Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J. Control. Release 135(1), 25-34 (2009).
46. Garg S, Kelly W: Insulin delivery via lungs - is it still possible? Diabetes Technol. Ther. 11(2 Suppl. 2), S1-S3 (2009).
47. Peppas N, Carr D: Impact of absorption and transport on intelligent therapeutics and nano-scale delivery of protein therapeutic agents. Chem. Eng. Sci. 64(22), 4553-4565 (2009).
48. Lee Y, Sinko P: Oral delivery of salmon calcitonin. Adv. Drug Deliv. Rev. 42(3), 225-238 (2000).
49. Patton J: Pulmonary delivery of drugs for bone disorders. Adv. Drug Deliv. Rev. 42(3), 239-248 (2000).
50. Deftos L, Nolan J, Seely B et al.: Intrapulmonary drug delivery of salmon calcitonin. Calcif. Tissue Int. 61(4), 345-347 (1997).
51. Yamamoto A, Okumura S, Fukuda Y, Fukui M, Takahashi K, Muranishi S: Improvement of the pulmonary absorption of (ASU1,7)-EEL calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J. Pharm. Sci. 86(10), 1144-1147 (1997).
52. Waldrep J, Arppe J, Jansa K, Vidgren M: Experimental pulmonary delivery of cyclosporin a by liposome aerosol. Int. J. Pharm. 160, 239-249 (1998).
53. Mitruka S, Pham S, Zeevi A et al.: Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J. Thorac. Cardiovasc. Surg. 115(1), 28-36, discussion 36-27 (1998).
54. Keenan R, Iacono A, Dauber J et al.: Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J. Thorac. Cardiovasc. Surg. 113(2), 335-340, discussion 340-331 (1997).
55. Letsou G, Saf H, Reardon M et al.: Pharmacokinetics of liposomal aerosolized cyclosporine a for pulmonary immunosuppression. Ann. Thorac. Surg. 68(6), 2044-2048 (1999).
56. Thipphawong J: Inhaled cytokines and cytokine antagonists. Adv. Drug Deliv. Rev. 58(9-10), 1089-1105 (2006).
57. Skubitz K, Anderson P: Inhalational interleukin-2 liposomes for pulmonary metastases: a Phase I clinical trial. Anticancer Drugs 11(7), 555-563 (2000).
58. Huland E, Heinzer H: Renal cell carcinoma - innovative medical treatments. Curr. Opin. Urol. 14(4), 239-244 (2004).
59. Huland E, Burger A, Fleischer J et al.: Effcacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol. (Praha) 49(5), 183-190 (2003).
60. Heinzer H, Mir T, Huland E, Huland H: Subjective and objective prospective, long-term ana lysis of quality of life during inhaled interleukin-2 immunotherapy. J. Clin. Oncol. 17(11), 3612-3620 (1999).
61. Hartig S, Greene R, Dasgupta J et al.: Multifunctional nanoparticulate polyelectrolyte complexes. Pharm. Res. 24(12), 2353-2369 (2007).
62. Mishra B, Patel B, Tiwari S: Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6(1), 9-24 (2010).
63. Crowder T, Rosati J, Schroeter J, Hickey A, Martonen T: Fundamental effects of particle morphology on lung delivery: predictions of stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 19(3), 239-245 (2002).
64. Oberdörster G, Oberdörster E, Oberdörster J: Nanotoxicology: an emerging discipline evolving from studies of ultrafne particles. Environ. Health Perspect. 113(7), 823-839 (2005).
65. Azarmi S, Tao X, Chen H et al.: Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int. J. Pharm. 319(1-2), 155-161 (2006).
66. Vega-Villa K, Takemoto J, Yáñez J, Remsberg C, Forrest M, Davies N: Clinical toxicities of nanocarrier systems. Adv. Drug Deliv. Rev. 60(8), 929-938 (2008).
67. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T: Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release 62(1-2), 279-287 (1999).
68. Grenha A, Seijo B, Remuñán-López C: Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25(4-5), 427-437 (2005).
69. Semmler-Behnke M, Takenaka S, Fertsch S et al.: Effcient elimination of inhaled nanoparticles from the alveolar region: Evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ. Health Perspect. 115(5), 728-733 (2007).
70. Dailey L, Jekel N, Fink L et al.: Investigation of the proinfammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 215(1), 100-108 (2006).
71. Azarmi S, Roa W, Löbenberg R: Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60(8), 863-875 (2008).
72. Kathuria H, Cao Y, Ramirez M, Williams M: Transcription of the caveolin-1 gene is differentially regulated in lung type I epithelial and endothelial cell lines. A role for ets proteins in epithelial cell expression. J. Biol. Chem. 279(29), 30028-30036 (2004).
73. Roy I, Vij N: Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 6(2), 237-244 (2010).
74. Brandenberger C, Mühlfeld C, Ali Z et al.: Quantitative evaluation of cellular uptake and traffcking of plain and polyethylene glycol-coated gold nanoparticles. Small 6(15), 1669-1678 (2010).
75. Zhu M, Feng W, Wang Y et al.: Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment. Toxicol. Sci. 107(2), 342-351 (2009).
76. Möller W, Felten K, Sommerer K et al.: Deposition, retention, and translocation of ultrafne particles from the central airways and lung periphery. Am. J. Respir. Crit. Care Med. 177(4), 426-432 (2008).
77. Arppe J, Vidgren M, Waldrep JC: Pulmonary pharmacokinetics of cyclosporin a liposomes. Int. J. Pharm. 161, 205-214 (1998).
78. Herber-Jonat S, Mittal R, Gsinn S, Bohnenkamp H, Guenzi E, Schulze A: Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated rats. Infamm. Res. DOI 10.1007/ s00011-010-0260-y (2010) (Epub ahead of print).
79. Videira M, Botelho M, Santos A, Gouveia L, De Lima J, Almeida A: Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target 10(8), 607-613 (2002).
80. Grenha A, Remuñán-López C, Carvalho E, Seijo B: Microspheres containing lipid/ chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur. J. Pharm. Biopharm. 69(1), 83-93 (2008).
81. Faraji A, Wipf P: Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 17(8), 2950-2962 (2009).
82. Huang Y, Wang C: Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 113(1), 9-14 (2006).
83. Bi R, Shao W, Wang Q, Zhang N: Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target 16(9), 639-648 (2008).
84. Chono S, Fukuchi R, Seki T, Morimoto K: Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Control. Release 137(2), 104-109 (2009).
85. Shahiwala A, Misra A: A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 6(3), E482-E486 (2005).
86. Gilbert B, Knight C, Alvarez F et al.: Tolerance of volunteers to cyclosporine a-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. 156(6), 1789-1793 (1997). (Pubitemid 28011783)
87. Khanna C, Hasz D, Klausner J, Anderson P: Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies. Clin. Cancer Res. 2(4), 721-734 (1996).
88. Khanna C, Anderson P, Hasz D, Katsanis E, Neville M, Klausner J: Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79(7), 1409-1421 (1997).
89. Ten R, Anderson P, Zein N, Temesgen Z, Clawson M, Weiss W: Interleukin-2 liposomes for primary immune defciency using the aerosol route. Int. Immunopharmacol. 2(2-3), 333-344 (2002).
90. Kaipel M, Wagner A, Wassermann E et al.: Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 281-290 (2008).
91. Lange C, Hancock R, Samuel J, Finlay W: In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J. Pharm. Sci. 90(10), 1647-1657 (2001).
92. Müller R, Petersen R, Hommoss A, Pardeike J: Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 59(6), 522-530 (2007).
93. Liu J, Gong T, Fu H et al.: Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 356(1-2), 333-344 (2008).
94. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z: Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev. 60(15), 1650-1662 (2008).
95. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky M, Yeo Y: Development of highly porous large plga microparticles for pulmonary drug delivery. Biomaterials 30(10), 1947-1953 (2009).
96. Huang X, Du Y, Yuan H, Hu F: Preparation and pharmacodynamics of low-molecular-weight chitosan nanoparticles containing insulin. Carbohydr. Poly. 76, 368-373 (2009).
97. Yamamoto H, Hoshina W, Kurashima H et al.: Engineering of poly(dl-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fuidized bed granulating system. Adv. Powder Technol.18(2), 215-228 (2007).
98. Grenha A: Microencapsulación De nanopartículas De quitosano para la administración pulmonar De macromoléculas terapéuticas. Universidad De Santiago De Compostela, Facultad De Farmacia, Departamento De Farmacia y Tecnología Farmacéutica. PhD Thesis, 306 (2006).
99. Zhang Q, Shen Z, Nagai T: Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm. 218(1-2), 75-80 (2001).
100. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y: Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 5(1), 77-85 (2000).
101. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y: Surface-modifed PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control. Release 102(2), 373-381 (2005).
102. Renwick L, Brown D, Clouter A, Donaldson K: Increased infammation and altered macrophage chemotactic responses caused by two ultrafne particle types. Occup. Environ. Med. 61(5), 442-447 (2004).
103. Chang C: The immune effects of naturally occurring and synthetic nanoparticles. J. Autoimmun. 34(3), J234-J246 (2010).
104. Thomas D, Myers M, Wichert B, Schreier H, Gonzalez-Rothi R: Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99(5), 1268-1270 (1991).
105. Lizio R, Klenner T, Sarlikiotis A et al.: Systemic delivery of cetrorelix to rats by a new aerosol delivery system. Pharm. Res. 18(6), 771-779 (2001).
106. Niven R, Whitcomb K, Woodward M, Liu J, Jornacion C: Systemic absorption and activity of recombinant consensus interferons after intratracheal instillation and aerosol administration. Pharm. Res. 12(12), 1889-1895 (1995).
107. Taljanski W, Pierzynowski S, Lundin P et al.: Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine a to young and adult rats. Drug Metab. Dispos. 25(8), 917-920 (1997).
108. Bennett D, Tyson E, Nerenberg C, Mah S, De Groot J, Teitelbaum Z: Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefy anesthetized dog. Pharm. Res. 11(7), 1048-1055 (1994).
109. Schreier H, Mcnicol K, Bennett D, Teitelbaum Z, Derendorf H: Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. Pharm. Res. 11(7), 1056-1059 (1994).
110. Patton JS, Trinchero P, Platz RM: Bioavailability of pulmonary delivered peptides and proteins - a-interferon, calcitonins and parathyroid hormones. J. Control. Release 28(1-3), 79-85 (1994).
111. Colthorpe P, Farr S, Smith I, Wyatt D, Taylor G: The infuence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm. Res. 12(3), 356-359 (1995).
112. Pfützner A, Mann A, Steiner S: Technosphere/insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther. 4(5), 589-594 (2002).
113. Pang Y, Sakagami M, Byron P: The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. Eur. J. Pharm. Sci. 25(4-5), 369-378 (2005).
114. Rave K, Bott S, Heinemann L et al.: Time-action profle of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28(5), 1077-1082 (2005
115. Niven R, Lott F, Cribbs J: Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (R-HUG-CSF) after intratracheal instillation to the hamster. Pharm. Res. 10(11), 1604-1610 (1993).
116. Hubbard R, Crystal R: Strategies for aerosol therapy of a1-antitrypsin defciency by the aerosol route. Lung 168(Suppl.), 565-578 (1990).
117. Kobayashi S, Kondo S, Juni K: Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13(1), 80-83 (1996).
118. Lizio R, Klenner T, Borchard G et al.: Systemic delivery of the gnrh antagonist cetrorelix by intratracheal instillation in anesthetized rats. Eur. J. Pharm. Sci. 9(3), 253-258 (2000).
119. Iacono A, Johnson B, Grgurich W et al.: A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. 354(2), 141-150 (2006).
120. Folkesson H, Weström B, Dahlbäck M, Lundin S, Karlsson B: Passage of aerosolized bsa and the nona-peptide dDAVP via the respiratory tract in young and adult rats. Exp. Lung Res. 18(5), 595-614 (1992).
121. Christopher F, Chase D, Stein K, Milne R: Rhdnase therapy for the treatment of cystic fbrosis patients with mild to moderate lung disease. J. Clin. Pharm. Ther. 24(6), 415-426 (1999).
122. Bitonti A, Dumont J, Low S et al.: Pulmonary delivery of an erythropoietin fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl Acad. Sci. USA 101(26), 9763-9768 (2004).
123. Russell K, Read M, Bellinger D et al.: Intratracheal administration of recombinant human factor IX (benefx) achieves therapeutic levels in hemophilia B dogs. Thromb. Haemost. 85(3), 445-449 (2001).
124. Onoue S, Yamamoto K, Kawabata Y, Hirose M, Mizumoto T, Yamada S: Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery. Int. J. Pharm. 382(1-2), 144-150 (2009).
125. Low S, Nunes S, Bitonti A, Dumont J: Oral and pulmonary delivery of fsh-fc fusion proteins via neonatal fc receptor-mediated transcytosis. Hum. Reprod. 20(7), 1805-1813 (2005).
126. Codrons V, Vanderbist F, Ucakar B, Préat V, Vanbever R: Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93(5), 1241-1252 (2004).
127. Codrons V, Vanderbist F, Verbeeck R et al.: Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 92(5), 938-950 (2003).
128. Van Zandwijk N, Jassem E, Dubbelmann R, Braat M, Rumke P: Aerosol application of interferon-a in the treatment of bronchioloalveolar carcinoma. Eur. J. Cancer 26(6), 738-740 (1990).
129. Martin P, Vaidyanathan S, Lane J et al.: Safety and systemic absorption of pulmonary delivered human IFN-b1a in the nonhuman primate: comparison with subcutaneous dosing. J. Interferon Cytokine Res. 22(6), 709-717 (2002).
130. Halme M, Maasilta P, Repo H et al.: Inhaled recombinant interferon-g in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int. J. Radiat. Oncol. Biol. Phys. 31(1), 93-101 (1995).
131. Eichelberg C, Andreas A, Heuer R, Huland H, Heinzer H, Huland E: Long-term tumor control with inhalational interleukin 2 therapy in cardiac high risk patients with metastatic renal carcinoma. J. Urol. 179(4), 167-167 (2008).
132. Adjei A, Sundberg D, Miller J, Chun A: Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. 9(2), 244-249 (1992).
133. Adjei A, Garren J: Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm. Res. 7(6), 565-569 (1990).
134. Tazawa R, Nakata K, Inoue Y, Nukiwa T: Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-macrophage colony-stimulating factor: a case report. Respirology 11(Suppl.) S61-S64 (2006).